Rallybio (RLYB)

• Market cap: $18.7M
• 1 day: -19.21%
• 5 days: -30.77%
• 1 month: -37.47%
• 3 months: -56.31%
• 6 months: -59.46%
• Year to date: -52.64%
• 1 year: -71.52%
• 5 years: -96.81%
• 10 years: -96.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Employees: 25

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1.11% more ownership

Funds ownership: 75.23% [Q3] → 76.34% (+1.11%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

2% less funds holding

Funds holding: 49 [Q3] → 48 (-1) [Q4]

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

17% less capital invested

Capital invested by funds: $36.5M [Q3] → $30.4M (-$6.11M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 1,011% upside
• Avg. target: $5 1,011% upside
• High target: $5 1,011% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 28% 1-year accuracy 51 / 182 met price target

1,011% upside $5

Buy Reiterated

17 Mar 2025